Organized breast screening: Answers to recurring controversies

Diagnostic and Interventional Imaging

Volumn 95, Issue 4, 2014, Pages 355-359

  Ceugnart, L ^a   Deghaye, M ^b   Vennin, P ^a   Haber, S ^c   Taieb, S ^a  

^a Oscar Lambret Cancer Center   (France)

^b Medical Imaging Center   (France)

^c NONE   (France)

Author keywords

Breast screening; Mammogram; Overdiagnosis

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; ECHOMAMMOGRAPHY; HEALTH PROGRAM; HUMAN; PUBLIC HEALTH; REVIEW; UNITED KINGDOM; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; STANDARDS;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS;

EID: 84900851113     PISSN: None     EISSN: 22115684     Source Type: Journal    
DOI: 10.1016/j.diii.2013.08.005     Document Type: Short Survey

References (26)

1. Ancelle-Park RM, Seradour B, Viguier J, et al. Spécificités et perspectives du programme fraņcais de dépistage organisé du cancer du sein. BEH 2012:391-4 [35.36.37].
2. Le dépistage du cancer du sein en question. Rev Que Choisir 2012; 507: 24-9.
3. Euroscreen working group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimates on benefit and harms balance sheet. J Med Screen 2012;19(Suppl. 1):5-13.
4. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380(9855):1778- 86.
5. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358(9290):1340-2.
6. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography (review). JohnWiley & Sons, Ltd; 2009 [onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD001877, The Cochrane collaboration].
7. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011;(1):CD001877.
8. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273(2):149-54.
9. Jorgensen KJ, Zahl PH, Gotzsche PC. Breast cancer mortality in organized mammography screening in Denmark: comparative study. BMJ 2010;340:c241.
10. Aouba A, Eb M, Rey G, Pavillon G, Jougla E. Données sur la mortalité en France : principales causes de décès en 2008 et évolutions depuis 2000. BEH 2011;22:249-55.
11. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010;363(13):1203-10.
12. Duffy S, Paci E. Bénéfices et risques du dépistage du cancer du sein par mammographie. BEH 2012:406-11 [35.36.37].
13. Hendrick RE, Helvie MA. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol 2012;198(3):723-8.
14. Zahl PH, Maehlen J, Welch HG. Natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008;168:2311-6.
15. Tabar L, Vitak B, Hsiu-Hsi Chen, et al. Swedish two county trial: impact of mammographic screening on breast cancer mortality during three decades. Radiology 2011;260(3):658-64.
16. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102(9):605-13.
17. Junod B, Zahl PH, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer 2011;11:401-7.
18. Bouée S, Grosclaude P, Alfonsi A, Florentin V, Clavel-Chapelon F, Fagnani F. Projection of the incidence of breast cancer in France in 2018. Bull Cancer 2010;97(3):293-9.
19. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 2011;260(3): 621-7.
20. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012;256:491-9.
21. Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T et al. Advanced breast cancer incidence following population based mammographic screening. Ann Oncol 2011;22:1726-35.
22. Allgood PC, Duffy SW, Kearins O, O'Sullivan E, Tappenden N, Wallis MG, et al. Explaining the difference in prognosis between screen detected and symptomatic cancers. Br J Cancer 2011;104:1680-5.
23. Riva C, Biollaz J, Foucras P, Junod B, Nicot P, Spinosa JP. Effect of population based screening on breast cancer mortality: response. Lancet 2012;379:1296.
24. Jorgensen KJ, Gotzsche P. Overdiagnosis in publicly organized screening programmes: systematic review of incidence trends. BMJ 2009;339:258726.
25. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, et al. Screening for breast cancer: an update for the US preventive task force. Ann Intern Med 2009;151: 727-37.
26. Rogel A, Lastier D, Salines E. Evaluation du programme national de dépistage organisé du cancer du sein en France : période 2004-2009. BEH 2012:399-404 [35.36.37].